Apolizumab: Difference between revisions

Browse history interactively ← Previous edit Next edit →Content deleted Content addedVisual WikitextInline

Revision as of 01:13, 26 April 2022 editFfffrr (talk \| contribs)Extended confirmed users99,459 edits Importing Wikidata short description: "Chemical compound" (Shortdesc helper)← Previous edit		Revision as of 20:20, 10 June 2022 edit undoWhywhenwhohow (talk \| contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,185 edits MOS:DATED Next edit →
Line 44:		Line 44:
	\| molecular_weight =		\| molecular_weight =
	}}		}}
	'''Apolizumab''' is a humanized ] intended for use in hematologic ]s.<ref>{{cite journal \| title = Gateways to clinical trials \| journal = Methods Find Exp Clin Pharmacol \| volume = 25 \| issue = 9 \| pages = 747–71 \| year = 2003 \| pmid = 14685303 \| author1 = Bayes M \| author2 = Rabasseda X \| author3 = Prous J }}</ref><ref>{{cite journal\|pmid=17071489\|year=2006\|last1=Rech\|first1=J\|last2=Repp\|first2=R\|last3=Rech\|first3=D\|last4=Stockmeyer\|first4=B\|last5=Dechant\|first5=M\|last6=Niedobitek\|first6=G\|last7=Gramatzki\|first7=M\|last8=Valerius\|first8=T\|title=A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study\|volume=47\|issue=10\|pages=2147–54\|doi=10.1080/10428190600757944\|journal=Leukemia & Lymphoma\|s2cid=24080973}}</ref>		'''Apolizumab''' is a humanized ] intended for use in hematologic ]s.<ref>{{cite journal \| title = Gateways to clinical trials \| journal = Methods Find Exp Clin Pharmacol \| volume = 25 \| issue = 9 \| pages = 747–71 \| year = 2003 \| pmid = 14685303 \| author1 = Bayes M \| author2 = Rabasseda X \| author3 = Prous J }}</ref><ref>{{cite journal \| pmid=17071489 \| year=2006 \| last1=Rech \| first1=J \| last2=Repp \| first2=R \| last3=Rech \| first3=D \| last4=Stockmeyer \| first4=B \| last5=Dechant \| first5=M \| last6=Niedobitek \| first6=G \| last7=Gramatzki \| first7=M \| last8=Valerius \| first8=T \| title=A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study \| volume=47 \| issue=10 \| pages=2147–54 \| doi=10.1080/10428190600757944 \| journal=Leukemia & Lymphoma \| s2cid=24080973}}</ref> Development was abandoned in 2005, because of toxic effects and lack of efficacy in humans. The observed dose limiting toxic effects were ] and ].<ref>{{cite journal \| vauthors=Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC \| title=A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia \| journal=Leuk. Lymphoma \| volume=50 \| issue=12 \| pages=1958–63 \| date=December 2009 \| pmid=19860603 \| doi=10.3109/10428190903186486 \| s2cid=22328921 \| url= \| pmc=8166408 }}</ref>

	Development was abandoned in 2005 because of toxic effects and lack of efficacy in human patients. The observed dose limiting toxic effects were ] and ].<ref>{{cite journal
	\|vauthors=Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC
	\|title=A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia
	\|journal=Leuk. Lymphoma
	\|volume=50
	\|issue=12
	\|pages=1958–63
	\|date=December 2009
	\|pmid=19860603
	\|doi=10.3109/10428190903186486
	\|s2cid=22328921
	\|url=
	\|pmc=8166408
	}}</ref> There are no current clinical trials into its use.<ref>{{Cite web\|url=http://adisinsight.springer.com/drugs/800006415\|title = Apolizumab - AdisInsight}}</ref>
	==References==		==References==
	{{reflist}}		{{reflist}}

Revision as of 20:20, 10 June 2022

Chemical compound Pharmaceutical compound

Apolizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	HLA-DR beta
Clinical data
ATC code	none
Identifiers
CAS Number	267227-08-7
ChemSpider	none
UNII	G88KCP51RE
KEGG	D02967
(what is this?) (verify)

Apolizumab is a humanized monoclonal antibody intended for use in hematologic cancers. Development was abandoned in 2005, because of toxic effects and lack of efficacy in humans. The observed dose limiting toxic effects were aseptic meningitis and hemolytic uremia.

References

Bayes M; Rabasseda X; Prous J (2003). "Gateways to clinical trials". Methods Find Exp Clin Pharmacol. 25 (9): 747–71. PMID 14685303.
Rech, J; Repp, R; Rech, D; Stockmeyer, B; Dechant, M; Niedobitek, G; Gramatzki, M; Valerius, T (2006). "A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study". Leukemia & Lymphoma. 47 (10): 2147–54. doi:10.1080/10428190600757944. PMID 17071489. S2CID 24080973.
Lin TS, Stock W, Xu H, Phelps MA, Lucas MS, Guster SK, Briggs BR, Cheney C, Porcu P, Flinn IW, Grever MR, Dalton JT, Byrd JC (December 2009). "A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia". Leuk. Lymphoma. 50 (12): 1958–63. doi:10.3109/10428190903186486. PMC 8166408. PMID 19860603. S2CID 22328921.

Monoclonal antibodies for the immune system

Immune system

Human	Immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive: Apolizumab Aselizumab Atezolizumab Benralizumab Camrelizumab Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Frexalimab Inebilizumab Itolizumab Lampalizumab Letolizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140 Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412 Immune activation: Dostarlimab Other: Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab Lebrikizumab Olokizumab Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatory lesions

Mouse	Besilesomab Fanolesomab Lemalesomab Sulesomab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: